Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for lomitapide to reduce cholesterol in patients with Homozygous Familial Hypercholesterolemia (HoFH).
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) said its Phase 2b PEARL-SC trial in pateints with systemic lupus erythematosus will continue following an interim analysis of all safety and efficacy data. Top-line efficacy data are expected in 2Q 2012.
Zalicus Inc. (NASDAQ: ZLCS) said that it intends to initiate a Phase 2 trial of Z160 for the treatment of neuropathic pain in 2H 2012.
XOMA Corporation (Nasdaq:XOMA) announced today that it is offering to sell shares of its common stock and corresponding warrants to purchase one half of a share of common stock for each share purchased.
Repligen Corporation (NASDAQ:RGEN) announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for SecreFlo™ to improve detection of pancreatic duct abnormalities in patients with pancreatitis.